Ripretinib in advanced gastrointestinal stromal tumors: an overview of current evidence and drug approval.
Sign Up to like & getrecommendations! Published in 2022 at "Future oncology"
DOI: 10.2217/fon-2022-0226
Abstract: Over the past 20 years, the management of gastrointestinal stromal tumors has acted as an important model in the advancement of molecularly targeted therapies for solid tumors. The success of imatinib has established it as a… read more here.
Keywords: stromal tumors; advanced gastrointestinal; evidence; ripretinib advanced ... See more keywords